Series B Completed
Aravax Series B
US$42.2m raised
Announced 23 Jan 2024
Investors
Investors
- Breakthrough Victoria
- Tenmile · Existing investor
- Novartis Venture Fund
- Uniseed
- Unisuper
- Agati Capital
- Brandon Capital Partners · Existing investor
Investors as the sources name them; a linked name has a FundComb profile. An existing investor is one the source says followed on.
- Company
- Aravax
- Stage
- Series B
- Amount raised
- US$42.2m
- Company based in
- Australia
Similar rounds
- Q-CTRL Series B-2 (expansion of Series B) Oct 2024 · A$87.5m · led by GP Bullhound
- Tabnine Series B Nov 2023 · A$39.2m · led by Titanium Ventures
- JigSpace Series B 2024 · A$13m · led by Breakthrough Victoria
- Prolific Machines Series B1 Jun 2024 · A$83.7m · led by Ki Tua Fund
- Hysata Series B May 2024 · led by bp Ventures
Sources
- 23 Jan 2024 Aravax breakthroughvictoria.com
- 23 Jan 2024 Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy brandoncapital.vc
- 23 Jan 2024 Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy brandonbiocatalyst.com